However, the resistance to imatinib develops in significant portions of patients under treatment, especially in those with CML in advanced stages or with Ph+ ALL, mostly due to the emergence of mutations in the BCR/ABL kinase domain. This evidence concerns the gene BCR and acute lymphoblastic leukemia.